Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 7353 - 7360 of 12093 results
Reexamination of "Healthy" Continues with an FDA Public Meeting in March 2017
February 20, 2017| Blog| Viewpoint
Update: DOL Regulation For Employers Who Use Direct Deposit and Payroll Debit Cards Invalidated
February 18, 2017| Blog| Viewpoint
The Future of the Affordable Care Act Week 6: Focus on the Individual Health Insurance Market
February 17, 2017| Blog| Viewpoint
FDA Hardens Its Stance on Intended Use and Off-Label Use and Industry Responds
February 17, 2017| Blog| Viewpoint
The Defend Trade Secrets Act: Securing Your Trade Secrets in 2017 LIVE Webcast
February 17, 2017| Blog| Viewpoint
US Patent Practice Drifting Toward Approach Prevalent Abroad
February 17, 2017| News
New York DOL Adopts Regulations Governing Employment Policies that Limit Employee Discussion of Wages
February 16, 2017| Blog| Viewpoint
The February 2017 Update – The Mintz Matrix
February 16, 2017| Blog| Viewpoint
News & Press Releases
Mintz advised the creators of Morbid, one of the top-charting true crime podcasts, in a multi-year agreement to move to SiriusXM from Wondery. The deal gives SiriusXM exclusive advertising rights for the audio and video formats of the podcast.
Mintz Advises CVC DIF in Acquisition of SBA Communications’ Canadian Tower Infrastructure Platform
August 06, 2025
Mintz advised CVC DIF, the dedicated infrastructure investment strategy of global private markets manager CVC, in its agreement to acquire SBA Communications’ Canadian wireless tower business, one of Canada’s leading independent owners and operators of wireless communications towers. The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions.
Mintz advised the underwriters in connection with a $69 million public offering by Larimar Therapeutics, Inc. of 21,562,500 shares of its common stock at a price to the public of $3.20 per share. The gross proceeds to Larimar from the offering were $69 million before deducting underwriting discounts and commissions and other offering expenses.
Events
Podcasts
Mintz On Air: Practical Policies - Investigations Unscripted
August 12, 2025| Podcast|
Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|
Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|